Kimberly Resnick

TL;DR: It is demonstrated that the extraction of RNA and subsequent identification of miRNAs from the serum of individuals diagnosed with ovarian cancer is feasible and real-time PCR-based microarray is a novel and practical means to performing high-throughput investigation of serum RNA samples.

TL;DR: Low-grade and high-grade endometrial stromal sarcomas represent two distinct clinical entities and should be treated as such and the need for aggressive cytoreduction is suggested.

TL;DR: This data is the first report providing evidence that the Wnt/β-catenin signaling pathway maintains stem-like properties and drug resistance of primary HGSOC PDX derived platinum resistant models, and therapeutic targeting of this pathway with iCG-001/PRI-724, which has been shown to be well tolerated in Phase I trials, may be an effective treatment option.

TL;DR: The addition of bevacizumab to standard chemotherapy in patients with advanced ovarian cancer is not cost effective and treatment with maintenance bevaccizumabs leads to improved PFS but is associated with both direct and indirect costs.

TL;DR: Treatment of advanced, recurrent, refractory epithelial ovarian cancer with bevacizumab and weekly taxane chemotherapy leads to significant, albeit temporary, improvement in the cancer-related symptoms in women treated on this regimen, and short-term exposure to these agents is not associated with significant toxicity.